New SGO evidence-based review on surgical management of cervical cancer in Gynecologic Oncology @gynoncjnls.
authors.elsevier.com/c/1o5CVKfi96B80
authors.elsevier.com/c/1o5CVKfi96B80
Alex Melamed
@headofmelon
Gynecologic Oncology practice @MassGenNews. Researching how real-world cancer care affects real-world patients. He/his/him/himself
1.2K Following 1.2K Followers 952 Posts
Latest posts 5
What an honor to work with the amazing team that has turned @IJGConline into an academic powerhouse! @pedroramirezMD, thank you for your mentorship and for being our captain years. @RParejaGineOnco, so excited for your leadership going forward!
Thank you, Alex @headofmelon for your outstanding service as IJGC #AssociateEditor 💙
💡 bit.ly/432CurA
@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaCondeView quoted post on X
Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.
For patients with advanced-stage ovarian cancer, higher utilization of neoadjuvant chemotherapy at high-volume centers was associated with the lowest 90-day surgical mortality and longest 60-month survival. ja.ma/415zwCxView quoted post on X
LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno
LANCE RCT: A minimally invasive surgery for advanced ovarian cancer after neoadjuvant chemotherapy is feasible and may reduce postoperative complications compared to laparotomy. ja.ma/4eBRbpzView quoted post on X